ClinicalTrials.gg
Sign In

Arthritis, Juvenile clinical trials

The registry lists 365 studies for Arthritis, Juvenile across more than 10 countries. 101 are recruiting or about to start. 278 of them are mainly about Arthritis, Juvenile (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Arthritis, Juvenile studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
182
Recruiting
69
Status unknown
38
Not yet recruiting
27
Terminated
21
Withdrawn
13

Phase

Phase 3
80
Phase 2
33
Phase 4
25
Phase 1
25
Early Phase 1
3

Where

United States
109
France
71
Italy
56
Germany
53
Canada
53
Spain
49

Who runs them

Novartis Pharmaceuticals (17) · Istanbul University - Cerrahpasa (13) · Hoffmann-La Roche (13) · The Hospital for Sick Children (11) · Assistance Publique - Hôpitaux de Paris (10) · Pfizer (9) · Swedish Orphan Biovitrum (9) · Amgen (9)

What is being tested here

Drugs under test in Arthritis, Juvenile studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Etanercept3712
Adalimumab369
Methotrexate349
Tocilizumab21220
Abatacept257
Tofacitinib246
Golimumab224
Secukinumab224
Upadacitinib213
Guselkumab223

Drug classes tested here JAK inhibitors 7 open · Tyrosine kinase inhibitors (TKIs) 7 open · Antimetabolites 4 open · NSAIDs 6 · COX-2 inhibitors 4

Coming up

19phase 3 studies under way
17studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger. 65 (94%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 11 (16%) take healthy volunteers.

Recruiting studies that take each age, of 69
AgeWomenMen
1058 (84%)58 (84%)
1848 (70%)48 (70%)
3023 (33%)23 (33%)
4022 (32%)22 (32%)
5022 (32%)22 (32%)
6519 (28%)19 (28%)
7519 (28%)19 (28%)
8519 (28%)19 (28%)

Across all 365 studies, recruiting or not: 82% stop at 75 or younger and 81% at 65; 93% take children; 2% are for women only and 1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Arthritis, Juvenile studies take

Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 342 mo30–70 · 36 studies——
Interventional, no phase14 mo8–39 · 56 studies—13 mo8–35 · 53 studies
Observational81 mo26–186 · 42 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Started recruiting1

Newly registered6

Show 1 more

Studies

Recruiting first, then most recently updated. Showing 50 of 365. Browse all 365 → or search them.